Jun 2, 2026
Abivax Shares Plunge Over 30% as Cancer Cases Overshadow Inflammatory Bowel Disease Trial Results
French biotech Abivax saw its stock tumble over 30% after reporting late-stage trial data for its ulcerative colitis drug, with investors focusing on safety concerns related to cancer cases despite the treatment showing efficacy.
2 sources
00